Saccharomyces boulardii, or S. boulardii, is a yeast that supplements sell as live cells. Trial reports also call it Saccharomyces cerevisiae var. boulardii. Products name strains by collection codes, such as CNCM I-745 or CNCM I-1079. Labels give the amount in milligrams or as a count of live cells.
Terms and sources
- a yeast
- NCCIH writes: "Other bacteria may also be used as probiotics, and so may yeasts such as Saccharomyces boulardii."
- Saccharomyces cerevisiae var. boulardii
- For example, ten Bruggencate et al., Eur J Clin Nutr, 2014. Some US labels use this name too.
- CNCM I-745
- Kabbani et al., Gut Microbes, 2016, also list CBS 5926 as another name for this strain.
- CNCM I-1079
- The strain in Karbownik et al., Nutrients, 2020. CNCM: the French national collection of microorganism cultures.
- milligrams or as a count
- NIH Dietary Supplement Label Database: amounts appear in mg, CFU or viable cells. We counted these.
S. boulardii in the body
S. boulardii is a live yeast, not a nutrient, and the body has no daily requirement for it. The trial below, in healthy adults, measured exam scores and pulse rate.
NIH ODS writes: "The International Scientific Association for Probiotics and Prebiotics defines probiotics as ‘live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.’" It continues: "These microorganisms, which consist mainly of bacteria but also include yeasts, are present in some fermented foods (e.g., yogurt), are added to certain food products, and are available as dietary supplements." It adds: "However, not all foods and dietary supplements that are labeled as probiotics have proven health benefits." NIH ODS notes: "Probiotics are identified by their genus, species, and strain designation; some probiotics also receive subspecies names." It adds: "Probiotic products often contain microbial organisms from the genera Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, Escherichia, and Bacillus and from the family Lactobacillaceae." In S. boulardii, Saccharomyces is the genus; a code such as CNCM I-745 marks the strain. NCCIH notes: "The most common are bacteria that belong to groups called Lactobacillus and Bifidobacterium." It continues: "Other bacteria may also be used as probiotics, and so may yeasts such as Saccharomyces boulardii." It adds: "Different types of probiotics may have different effects."
Terms and sources
- NIH ODS writes
- From the International Scientific Association for Probiotics and Prebiotics, 2014, as quoted by NIH ODS.
- NIH ODS notes
- The whole NIH ODS paragraph under "Identification", in two sentences. NIH Office of Dietary Supplements, fact sheet for health professionals.
- NCCIH notes
- Parts of two NCCIH paragraphs on the microbes in probiotics. Probiotics: Usefulness and Safety.
Yeast cells are much larger than bacterial cells, Karbownik and colleagues write. They add that yeast cell walls differ and that yeasts are less able to colonize the gut. They write that S. boulardii survives in the healthy human gut for no more than a few days. They caution that their results cannot be generalized to other strains, such as CNCM I-745.
Terms and sources
- Karbownik and colleagues
- Karbownik et al., Nutrients, 2020, in the discussion of their trial of strain CNCM I-1079.
- no more than a few days
- The authors cite earlier work for this.
NIH ODS notes: "Probiotics are unlikely to cause harm in healthy people, and side effects are usually minor." It continues: "However, the use of probiotics has been linked to a few cases of bacteremia, fungemia, and infections that have resulted in severe illness; most of these cases involved individuals who were severely ill or immunocompromised." NIH ODS adds: "At least 60 reports have been published since 1966 of fungemia associated with the use of probiotics that contain the yeast Saccharomyces cerevisiae." It continues: "In many of these cases, the patients were in an intensive care unit (ICU), were receiving enteral or parenteral nutrition, had a central venous catheter, or had received broad-spectrum antimicrobial treatment." NCCIH says: "Probiotics have an extensive history of apparently safe use, particularly in healthy people." It continues: "However, few studies have looked at the safety of probiotics in detail, so there’s a lack of solid information on the frequency and severity of side effects." NCCIH adds: "The risk of harmful effects from probiotics is greater in people with severe illnesses or compromised immune systems." It continues: "When probiotics are being considered for high-risk individuals, such as premature infants or seriously ill hospital patients, the potential risks of probiotics should be carefully weighed against their benefits." NCCIH notes: "Cases of severe or fatal infections have been reported in premature infants who were given probiotics, and the U.S. Food and Drug Administration (FDA) has warned health care providers about this risk." It adds: "Possible harmful effects of probiotics include infections, production of harmful substances by the probiotic microorganisms, and transfer of antibiotic resistance genes from probiotic microorganisms to other microorganisms in the digestive tract." NCCIH also says: "Some probiotic products have been reported to contain microorganisms other than those listed on the label." It continues: "In some instances, these contaminants may pose serious health risks." NCCIH advises: "Don’t use probiotics as a reason to postpone seeing your health care provider about any health problem." It adds: "If you’re considering a probiotic dietary supplement, consult your health care provider first." It continues: "This is especially important if you have health problems." And: "Anyone with a serious underlying health condition should be monitored closely while taking probiotics."
Terms and sources
- NIH ODS notes
- The first paragraph of the Safety Considerations section of the NIH ODS probiotics fact sheet for health professionals. The section has six paragraphs; the two sentences on yeast below are from the fifth.
- It continues
- Bacteremia and fungemia: bacteria or fungi, such as yeasts, in the blood (our explanation).
- NIH ODS adds
- From the fifth paragraph of the same Safety Considerations section. S. boulardii is also named Saccharomyces cerevisiae var. boulardii.
- NCCIH says
- The whole section, in four points, as NCCIH wrote it. Then two of the three points under "More To Consider".
Where S. boulardii comes from
The study below gave S. boulardii in capsules. It used strain CNCM I-1079, from a product sold in Poland. In another trial, the yeast was strain CNCM I-745, in a product of Biocodex Inc.
Terms and sources
- in capsules
- Karbownik 2020: one capsule a day of a product sold in Poland, moved into new capsules with maltodextrin.
- strain CNCM I-1079
- Karbownik et al., Nutrients, 2020.
- strain CNCM I-745
- Kabbani et al., Gut Microbes, 2016. Biocodex Inc. and an NIH award funded the trial. Not shown below: other groups in that trial took an antibiotic.
NIH ODS notes: "Some types of fermented foods, such as yogurt, are potential sources of beneficial microbes, though not all fermented foods that contain live cultures have probiotic microorganisms." It adds: "Probiotic microorganisms are also sometimes added to unfermented foods."
Terms and sources
- NIH ODS notes
- The whole NIH ODS paragraph under "Food", in two sentences.
Daily amounts and the upper limit
NIH ODS notes: "There are currently no formal recommendations for or against the use of probiotics in healthy people." It adds: "However, some expert bodies of health professionals provide guidance on the use of specific probiotic strains in people with certain health conditions." It continues: "These groups also offer guidance for clinicians and consumers on choosing probiotic products."
Terms and sources
- NIH ODS notes
- The first paragraph of the NIH ODS section "Probiotic Selection and Use".
United States
There is no US recommended daily amount for S. boulardii. The National Academies have not set an upper limit for S. boulardii.
NCCIH notes: "Government regulation of probiotics in the United States is complex." It adds: "Depending on a probiotic product’s intended use, the FDA might regulate it as a dietary supplement, a food ingredient, or a drug."
Terms and sources
- NCCIH notes
- National Center for Complementary and Integrative Health, Probiotics: Usefulness and Safety.
In the NIH label database, 638 US labels name S. boulardii in an ingredient or form entry. Another 948 labels name Saccharomyces without boulardii. Of the 638, 403 also name bacteria, and 235 name no other microbe. On 87 of the 638 labels, the S. boulardii entry names a strain code.
Terms and sources
- 638 US labels
- NIH Dietary Supplement Label Database, 214,768 labels, including products no longer sold. Whole-word search for boulardii, or the codes CNCM I-745, I-1079 or I-3799, within one entry. We counted these.
- 948 labels
- These labels are not counted below. We counted these.
- 403 also name bacteria
- Bacteria named in any entry of the label. We counted these.
- 87 of the 638
- CNCM I-1079 on 20 labels, I-3799 on 20 and CNCM I-745 on 3. Other codes on 44. We counted these.
Of the 235 labels with no other microbe, 112 give an amount in mg for S. boulardii. Of the 235, 101 give a count in billions in the label text.
Terms and sources
- 112 give an amount in mg
- 250 mg on 50 labels, 500 mg on 23, 450 mg on 14 and 1,000 mg on 10. We counted these.
- 101 give a count in billions
- 5 billion on 68 labels, 2 of which also give 20 billion. 10 billion on 15, 3 billion on 11. Labels word the count as CFU, cells or cultures. We counted these.
Published studies of S. boulardii
Many trials of S. boulardii enrolled children, people with a diagnosis or people taking antibiotics. Those trials, trials of blends and trials that counted illness episodes are not listed here.
1 study in healthy adults: it found a difference in pulse rate only.
Not listed: studies in which some or all volunteers also took an antibiotic. Also not listed: a trial in which some participants took a medicine: contraceptive pills required for entry. Also not listed: a trial in travelers that counted illness episodes. Also not listed: studies without a dummy group, one with gut samples taken by endoscopy. Also not listed: a study that compared healthy volunteers with people chosen for a diagnosis, without stated randomization. Also not listed: studies with products taken in turn, in a fixed order or with no stated random order. Also not listed: products that combine the yeast with bacteria or other ingredients, including one given with a bacterial challenge. Also not listed: other reports of trials shown here.
Our one-line summary comes first. The original is on PubMed.
Show the study
Students took S. boulardii before an exam; scores did not differ; pulse rose more than with dummy capsules.
Trial · 92 randomized to three groups; 60 to S. boulardii (31) or dummy capsules (29); 50 completed (25 and 25). The third group (an LGG product, found degraded) is reported separately. The second report counts 51 completers. · 30 days
Karbownik et al., Nutrients, 2020
Terms and sources
- Students
- 92 healthy medical students in Poland were randomized to three groups. 60 went to S. boulardii (31) or dummy capsules (29); 50 completed. A third group took an LGG product found degraded after the trial; the authors report it separately. Another report of this trial had data from 32 participants. Salivary serotonin was sampled at rest and the day before the exam. Its change was 3.13 ng/mL lower than with dummy capsules (p = 0.037). People on regular medicines were excluded; hormonal contraceptives were allowed.
- S. boulardii
- Strain CNCM I-1079. The authors bought the product in Poland; The product is listed as from Institut Rosell, Montreal, Canada. Its contents were moved into new capsules with maltodextrin. Declared 5 billion CFU per capsule, one capsule a day for 30 days.
- scores did not differ
- Final exam scores were 41.9 with S. boulardii and 40.1 with dummy capsules; the difference was not statistically significant (p = 0.18). The rise in self-rated tension scores and salivary cortisol before the exam did not differ between groups. Neither did the change in salivary metanephrine (p = 0.10).
- pulse rose more
- Self-measured pulse before the exam rose by 21.4 beats a minute with S. boulardii and by 11.0 with dummy capsules (p = 0.0018). The authors write: "it seems to increase pulse rate under stress, which may hypothetically reflect enhanced sympathoadrenal activity." They add that self-measured pulse has limited validity.
- dummy capsules
- Placebo capsules filled with maltodextrin only, identical in look. Participants could not tell which product they took. In all three groups, 26 of those who completed (34%) reported any adverse event; the groups did not differ.
Study · Free full text · about 37 min to read
Our estimate at about 200 words a minute, from the PMC full text.
Study summary
Ninety-two healthy medical students in Poland were randomized to S. boulardii CNCM I-1079, an LGG product or dummy capsules. They took one capsule a day for 30 days before a pharmacology exam. The LGG product was found degraded and is reported separately. Of 60 students in the S. boulardii and dummy groups, 50 completed. Exam scores did not differ significantly. The rise in self-rated tension scores and salivary cortisol did not differ. Self-measured pulse rose more with S. boulardii: by 21.4 versus 11.0 beats a minute. The trial was registered after it ended. Funding: grants from the Medical University of Lodz; the authors declare no conflicts.
Information, not a prescription. Do not start, stop or combine supplements or medicines on your own.